DanielWarrenSeekinsMD
Infectious Disease • Lawrenceville, NJHIV/AIDS Medicine
Vice President, Hematology and Cell Therapy, Medical Safety Assessment, Bristol-Myers Squibb
Dr. Seekins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3401 Princeton Pike
Mailstop: B2.064
Lawrenceville, NJ 08648Phone+1 609-302-4132- Is this information wrong?
Education & Training
University of FloridaFellowship, Infectious Disease, 1989 - 1991
HCA Healthcare/Mercer University School of Medicine/Memorial Health University Medical CenterResidency, Internal Medicine, 1986 - 1989- University of Florida College of MedicineClass of 1986
Certifications & Licensure
FL State Medical License 1989 - 2025
GA State Medical License 1987 - 1997- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors
- A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor Start of enrollment: 2001 Aug 01
Publications & Presentations
PubMed
- Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar ...> ;Annals of internal medicine.
- 17 citationsNo evidence of an association between efavirenz exposure and suicidality among HIV patients initiating antiretroviral therapy in a retrospective cohort study of real w...Ella Nkhoma, John Coumbis, Amanda M. Farr, Stephen S. Johnston, Bong Chul Chu, Lisa Rosenblatt, Daniel Seekins, Angelina Villasis-Keever> ;Medicine. 2016 Jan 1
- 10 citationsOverview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.J. Hey-Hadavi, Daniel Seekins, Melissa Palmer, Denise Coffey, John Caminis, Sandzhar Abdullaev, Meenal Patwardhan, Haifa Tyler, Ritu Raheja, Ann Marie Stanley, Liliam ...> ;Drug Safety. 2021 Mar 16
- Join now to see all
Press Mentions
Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical TrialsMarch 16th, 2021
Professional Memberships
- Member
- Member
Industry Relationships
- Group Medical Director, CV/Fibrosis/Immunoscience Medical Safety Assessment Lead, Bristol-Myers Squibb2003 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
